Tánczos Bence, Vass Virág, Szabó Erzsébet, Lovas Miklós, Kattoub Rasha Ghanem, Bereczki Ilona, Borbás Anikó, Herczegh Pál, Tósaki Árpád
Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; HUN-REN-DE Pharmamodul Research Group, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary.
Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; HUN-REN-DE Pharmamodul Research Group, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98, Hungary; Doctoral School of Pharmaceutical Sciences, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98., Hungary.
Eur J Pharm Sci. 2024 Apr 1;195:106721. doi: 10.1016/j.ejps.2024.106721. Epub 2024 Feb 6.
Hydrogen sulfide (HS), a gasotransmitter, plays a crucial role in vasorelaxation, anti-inflammatory processes and mitigating myocardial ischemia/reperfusion-induced injury by regulating various signaling processes. We designed a water soluble HS-releasing ascorbic acid derivative, BM-164, to combine the beneficial cardiovascular and anti-inflammatory effects of HS with the excellent water solubility and antioxidant properties of ascorbic acid. DPPH antioxidant assay revealed that the antioxidant activity of BM-164 in the presence of a myocardial tissue homogenate (extract) increased continuously over the 120 min test interval due to the continuous release of HS from BM-164. The cytotoxicity of BM-164 was tested by MTT assay on H9c2 cells, which resulted in no cytotoxic effect at concentrations of 10 to 30 μM. The possible beneficial effects of BM-164 (30 µM) was examined in isolated 'Langendorff' rat hearts. The incidence of ventricular fibrillation (VF) was significantly reduced from its control value of 79 % to 31 % in the BM-164 treated group, and the infarct size was also diminished from the control value of 28 % to 14 % in the BM-164 treated group. However, coronary flow (CF) and heart rate (HR) values in the BM-164 treated group did not show significantly different levels in comparison with the drug-free control, although a non-significant recovery in both CF and HR was observed at each time point. We attempted to reveal the mechanism of action of BM-164, focusing on the processes of autophagy and apoptosis. The expression of key autophagic and apoptotic markers in isolated rat hearts were detected by Western blot analysis. All the examined autophagy-related proteins showed increased expression levels in the BM-164 treated group in comparison to the drug-free control and/or ascorbic acid treated groups, while the changes in the expression of apoptotic markers were not obvious. In conclusion, the designed water soluble HS releasing ascorbic acid derivative, BM-164, showed better cardiac protection against ischemia/reperfusion-induced injury compared to the untreated and ascorbic acid treated hearts, respectively.
硫化氢(HS)作为一种气体信号分子,通过调节各种信号传导过程,在血管舒张、抗炎过程以及减轻心肌缺血/再灌注损伤方面发挥着关键作用。我们设计了一种水溶性的释放HS的抗坏血酸衍生物BM - 164,旨在将HS对心血管有益和抗炎的作用与抗坏血酸出色的水溶性及抗氧化特性相结合。二苯基苦味酰基自由基(DPPH)抗氧化试验表明,在心肌组织匀浆(提取物)存在的情况下,由于BM - 164持续释放HS,BM - 164的抗氧化活性在120分钟的测试间隔内持续增强。通过MTT法检测BM - 164对H9c2细胞的细胞毒性,结果发现在10至30μM的浓度下无细胞毒性作用。在离体“Langendorff”大鼠心脏中研究了BM - 164(30μM)可能的有益作用。在BM - 164治疗组中,室颤(VF)发生率从对照组的79%显著降低至31%,梗死面积也从对照组的28%减小至14%。然而,与无药物对照组相比,BM - 164治疗组的冠状动脉血流量(CF)和心率(HR)值未显示出显著差异,尽管在每个时间点CF和HR均有不显著的恢复。我们试图揭示BM - 164的作用机制,重点关注自噬和凋亡过程。通过蛋白质免疫印迹分析检测离体大鼠心脏中关键自噬和凋亡标志物的表达。与无药物对照组和/或抗坏血酸治疗组相比,所有检测的自噬相关蛋白在BM - 164治疗组中的表达水平均升高,而凋亡标志物表达的变化不明显。总之,所设计的水溶性释放HS的抗坏血酸衍生物BM - 164分别与未处理心脏和抗坏血酸处理的心脏相比,对缺血/再灌注损伤表现出更好的心脏保护作用。